Continue from research to sourcing
Compare Tesamorelin listings without losing the evidence context
Tesamorelin has a product-specific approval history, but research-market listings do not inherit that status. This page compares only their observable catalog and documentation records.
Identity first
Confirm the stabilized GHRH analog, expected sequence and labeled quantity. Do not treat an ingredient name as proof of approved-product equivalence.
Normalize price
Several vial sizes may appear under one catalog page, so PDD separates exact strengths and calculates price per mg.
Inspect evidence
Review lot traceability, identity, purity, content and whether the report corresponds to the exact strength offered.
How Tesamorelin is used in research
Tesamorelin stimulates pituitary growth-hormone release through the GHRH receptor. Clinical development measured body-composition and metabolic endpoints in a defined patient population.
Approval is product-specific. A bulk or research material labeled tesamorelin is not equivalent to an FDA-approved finished prescription product.
Evidence map
Research stage matters. Findings from one model should not be silently promoted to another.
Laboratory
Receptor and stability studies support its GHRH-analog classification.
Animal
Preclinical endocrine testing preceded clinical development.
Human
Controlled trials supported specific FDA-approved prescription products.
What the evidence does not establish
Approved labeling has a defined population, contraindications, and monitoring context. It cannot support off-label marketing of unrelated materials.
Study findings also do not authenticate a supplier’s material. Biological plausibility, a familiar name, or a published paper cannot substitute for lot-specific identity and quality evidence.
Analytical and documentation checks
The test plan should match the exact molecule, modification, and research question.
- Confirm the trans-3-hexenoic-acid modification and full sequence.
- Differentiate active ingredient identity from finished-product equivalence.
- Review impurity, content, and stability evidence separately.
At minimum, connect the product name, sequence, sample identifier, lot, report, method, expected result, and observed result. Record untested attributes as “not reported,” not as assumed passes.
Build the documentation record
Regulatory status
FDA-approved prescription products containing tesamorelin exist for a defined indication. Other materials do not inherit that approval.
Regulatory status can change and attaches to specific products and jurisdictions. Verify current official records before publishing, procuring, or relying on a status claim.
Primary sources and official records
Use these records as starting points, then assess the exact model, test article, methods, and date:
Peptide Due Diligence Research Brief
Follow the evidence, not the headline.
Receive new evidence maps, documentation guides, and material corrections as the directory expands.
By subscribing, you agree to receive PDD research emails. Unsubscribe at any time.
Already subscribed? Get your free checklist.